Skip to main content
SpringerLink
Log in

Targeting Angiogenic Pathways Involving Tumor–stromal Interaction to Treat Advanced Human Prostate Cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Interfering with and preventing tumor angiogenesis is an attractive therapeutic approach for treating cancer metastases. This commentary presents treatment strategies that may enhance the effectiveness of anti-angiogenic therapy by selectively targeting newly sprouting and immature vessels, inhibiting the production of angiogenic factors, and disrupting extracellular matrices. We propose several clinical paradigms, including hormonal ablation, intermittent androgen suppression, chemotherapy, and radiation therapy, that ‘injure’ nascent vasculature and interrupt the cancer cell–stromal relationship, thereby potentiating the efficacy of experimental anti-angiogenic agents. These stromal–epithelial interactions play an important role in the development, proliferation and dissemination of prostate cancer, as well as guiding the processes of tumor neovascularization. Successful utilization and targeting of tumor angiogenesis requires an increased understanding of tumor cell–stromal cell–endothelial cell relationships, most notably the intricate intracellular signalling cascades mediated by growth factors and the extracellular matrix.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Canc 33: 566-574, 1997

    Article  Google Scholar 

  2. Bane RL, Torti FM. Endocrine therapy for prostate cancer. Canc Treat Res 94: 69-87, 1998

    Google Scholar 

  3. Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth in vivoby prostate and bone fibroblasts. Canc Res 51: 3753-3761, 1991

    Google Scholar 

  4. Chung LWK: Implications of stromal-epithelial interaction in human prostate cancer growth, progression, and differentiation. Sem Canc Biol 4: 183-192, 1993

    Google Scholar 

  5. Chung LWK: Stromal-epithelial interactions dictate prostate cancer androgen independent metastatic progression. Canc Det Prev 22(Supplement 1): 57-58, 1998

    Article  Google Scholar 

  6. Ellis LM, Fidler IJ: Angiogenesis and Metastasis. Eur J Canc 32A: 2451-2460, 1996

    Article  Google Scholar 

  7. Weinstat-Saslow D, Steeg P: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8: 401-407, 1994

    PubMed  Google Scholar 

  8. Polverini PJ: How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Canc 32A: 2430-2437, 1996

    Article  Google Scholar 

  9. Folkinan J: Clinical applications of research on angiogenesis. New Engl J Med 333: 1757-1763, 1995

    Article  PubMed  Google Scholar 

  10. Boehm T, Folkman J, Bowder T, O'Reilly MS: Anti-angiogenic therapy of experimental cancer does not induce drug resistance. Nature 390: 404-407, 1997

    Article  PubMed  Google Scholar 

  11. Sokoloff MH, Bradley MJ, Zhau HE, Williams JI, Chung LWK: Downregulation of integrin αvβ3 expression by squalamine obliterates advanced human prostate cancer. Submitted

  12. Sills AK, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H: Squalamine inhibits angiogenesis and solid tumor growth in vivoand perturbs embryonic vasculature. Canc Res 58: 2784-2792, 1998

    Google Scholar 

  13. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D: Potential of the aminosterol squalamine in combination therapy in rat mammary carcinoma and murine Lewis lung carcinoma. Anticancer Res 18: 2567-2573, 1998

    PubMed  Google Scholar 

  14. Brooks PC: Role of integrins in angiogenesis. Eur J Canc 32A: 2423-2429, 1996

    Article  Google Scholar 

  15. Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G: Role of soluble mediators in angiogenesis. Eur J Canc 32A: 2401-2412, 1996

    Article  Google Scholar 

  16. Ausprunk DH, Folkrnan J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65, 1977

    Article  PubMed  Google Scholar 

  17. Paku S, Paweletz N: First steps in tumor-related angiogenesis. Lab Invest 65: 334-346, 1991

    PubMed  Google Scholar 

  18. Folkman J, Cotran R: Relation of vascular proliferation to tumor growth. Internat Rev Exp Pathol 16: 207-248, 1976

    Google Scholar 

  19. Folkman J, Klagsburn M: Angiogenic factors. Science 235: 442-447, 1987

    PubMed  Google Scholar 

  20. Pepper MS: Manipulating angiogensis: from basic science to the bedside. Arterioscle Throm Vasc Biol 17: 605-619, 1997

    Google Scholar 

  21. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cel Biochem 17: 4015-4023, 1997

    Google Scholar 

  22. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev 13: 18-32, 1992

    Article  Google Scholar 

  23. Ferrara N: Vascular endothelial growth factor. Eur J Canc 32A: 2413-2422, 1996

    Article  Google Scholar 

  24. Claffet KP, Robinson GS: Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Canc Metast Rev 15: 165-1996

  25. Jackson MW, Bentel JM, Tillet WD: Vascular endothelial growth factor expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328, 1997

    Article  PubMed  Google Scholar 

  26. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situand in vitroexpression of VEGF by human prostate cancer cells. J Urol 157: 2329-2333, 1997

    Article  PubMed  Google Scholar 

  27. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivoand in vitroexpression of angiogenesis factors by prostate cancer cells. Urology 51: 161-167, 1998

    Article  Google Scholar 

  28. Weidner N, Carroll PR, Flax J, Blumenthal W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am J Pathol 143: 401-409, 1993

    PubMed  Google Scholar 

  29. Joseph IBJK, Nelson JB, Denmeade SR, Isaacs JT: Androgens regfulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Canc Res 3: 2507-2511, 1997

    Google Scholar 

  30. Joseph IBJK, Isaacs JT: Potentiation of anti-angiogenic ability of Linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Canc Res 57: 1054-1057, 1997

    Google Scholar 

  31. Varner JA, Cheresh DA: Integrins and cancer. Curr Opin Cell Biol 8: 724-730, 1996

    Article  PubMed  Google Scholar 

  32. Thalmann GN, Anezmis PE, Chang S-M, Zhau HE, Kim E, Nopwood VL, Pathak S, von Eschenbach AC, Chung LWK: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Canc Res 54: 2577-2581, 1994

    Google Scholar 

  33. Thalmann GN, Anezinis PE, ChungL WK, Devoll R, Farach-Carson C: Experimental approaches to skeletal metastasis of human prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, 1996, pp 409-416

    Google Scholar 

  34. Cherish DA: Death to a blood vessel, death to a tumor. Nature Medicine 4: 395-396, 1998

    Article  PubMed  Google Scholar 

  35. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha-v beta-3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994

    Article  PubMed  Google Scholar 

  36. Brooks PC, Clark RAF, Cheresh DA: Requirement of vascular integrin alpha-v beta-3 for angiogenesis. Science 264: 569-571, 1994

    PubMed  Google Scholar 

  37. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostate cancer: the role of neovascualrity. Cancer 73: 678-672, 1994

    PubMed  Google Scholar 

  38. Silberman MA, Partin AW, Veltri RW, Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997

    Article  PubMed  Google Scholar 

  39. Woessner RD, Wright PS, Loudy DE, Wallace CD, Montgomery LR, Nestok BR: Microautoradiographic quantitation of vascular endothelial growth actor mRNA levels in human prostate specimens containing normal and neoplastic epithelium. Exp Mol Pathol 65: 37-52, 1998

    Article  PubMed  Google Scholar 

  40. Brawer MK: Neovascularity in human prostate cancer. In: Belldegrun A, Kirby RS, Oliver T (eds) New Perspectives in Prostate Cancer. Isis, Oxford, 1998, pp 71-76

    Google Scholar 

  41. Paulson DF: Treatment of localized cancer of the prostate. In: Lepor H, Lawson RK (eds) Prostate Diseases. WB Saunders, Philadelphia, 1993, pp 368-377

    Google Scholar 

  42. Schellhammer PF: Radical prostatectomy: patterns of local failure and survival. Urology 31: 191-7, 1988

    Article  PubMed  Google Scholar 

  43. Lerner SP, Seale-Hawkins C, Carlton CE, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146: 1040-50, 1991

    PubMed  Google Scholar 

  44. Catalona WJ, Dresner SM: Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 134: 1149-55, 1985

    PubMed  Google Scholar 

  45. Lu-Yao G, McLarran D, Wasson J, Wennberg JE: An assessment of radical prostatectomy. J Am Med Ass 269: 2633-36, 1993

    Article  Google Scholar 

  46. Scher HI, Chung LWK: Bone metastasis: improving the therapeutic index. Sem Oncol 21: 630-656, 1994

    Google Scholar 

  47. Shibata A, MAJ, Whittemore AS: Prostate cancer incidence and mortality in the United States and United Kingdom. J Nat Canc Inst 90: 1230-1231, 1998

    Article  Google Scholar 

  48. Granfors T, Modig H, Danber JE, Tomic R: Combined orchiectomy and radation therapy for nonmetastatic prostate cancer. J Urol 159: 2030-2034, 1998

    Article  PubMed  Google Scholar 

  49. Dameron KM, Volpert OV, Tainsky MA, Bouch N: Control of angiogenesis in fibroblasts by p53 regulation of thrmobospondin-1. Science 265: 1582-1584, 1994

    PubMed  Google Scholar 

  50. Ruley HE: p53 and response to chemotherapy and radiotherapy. Imp Adv Oncol, 1996, pp 37-56

  51. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial derived growth factor mediated signaling in mouse messentary vascular endothelium. Canc Res 58: 1278-1284, 1998

    Google Scholar 

  52. Folkinan J: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence (editorial). Endocrinol 139: 441-442, 1998

    Article  Google Scholar 

  53. Frank-Lissbrant I, Haggstrom S, Damber J-E, Bergh A: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinol 139: 451-456, 1998

    Article  Google Scholar 

  54. Haggstrom S, Wikstrom P, Bergh A, Damber J-E: Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adeno-carcinoma before and after castration. Prostate 36: 71-79, 1998

    Article  PubMed  Google Scholar 

  55. Jain RK, Safabakhsh N, Sckell A, ChenY, Jiang P, Benjamin L, Yuan F, Keshet E: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Nat Ac Science 95: 10820-10825, 1998

    Article  Google Scholar 

  56. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate specific antigen gene in the LNCaP prostate tumor model. J Ster Biochem Mol Biol 58: 139-146, 1996

    Article  Google Scholar 

  57. Theyer G, Hamilton G: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urol 52: 353-359, 1998

    Article  PubMed  Google Scholar 

  58. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer. Urol 47: 956-961, 1995

    Google Scholar 

  59. Higano CS, Ellis W, Russel K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. Urol 48: 800-804, 1996

    PubMed  Google Scholar 

  60. Zhau HE, Chang S-M, Chen B-Q, Wang Y-L, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK: Androgen-repressed phenotype in human prostate cancer. Proc Nat Ac Science 93: 15152-15157, 1996

    Article  Google Scholar 

  61. Fajardo LF, Berthrong M: Vascular lesions following radiation. Path Ann 23: 297-300, 1988

    Google Scholar 

  62. Fajardo LF: Morphology of radiation effects on normal tissues. In: Perez CA, Brady LW(eds) Princ Prac Rad Oncol. Lippincott, Philadelphia, 1997, pp 143-154

    Google Scholar 

  63. Hudes OR, Natha F, Khater C, Haas N, Cornbfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Rosss E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustine phospate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-63, 1997

    PubMed  Google Scholar 

  64. Pienta KJ, Smith DC: Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Sem Oncol 24(Supplement 5): 72-75, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Urology and Therapeutics Program, Department of Urology, University of Virginia, Charlottesville, Virginia, 22908, USA

    Mitchell H. Sokoloff & Leland W.K. Chung

Authors
  1. Mitchell H. Sokoloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leland W.K. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sokoloff, M.H., Chung, L.W. Targeting Angiogenic Pathways Involving Tumor–stromal Interaction to Treat Advanced Human Prostate Cancer. Cancer Metastasis Rev 17, 307–315 (1998). https://doi.org/10.1023/A:1006170612253

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006170612253

Search

Navigation